Comparison of pulsed actinomycin D and 5‐day actinomycin D as first‐line chemotherapy for low‐risk gestational trophoblastic neoplasia
Authors:
- 16 August 2018
- journal article
- research article
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 143 (2) , 225-231
Abstract
Objective: To compare the treatment outcome and cost‐effectiveness of pulsed actinomycin D (Act‐D) and 5‐day Act‐D in patients with low‐risk gestational trophoblastic neoplasia (GTN).Method: The present retrospective study included patients with low‐risk GTN who received pulsed Act‐D or 5‐day Act‐D as first‐line chemotherapy at West China Second Hospital, Chengdu, China, between January 1, 2016, and December 31, 2017. Complete remission rates, mean number of treatment courses, and adverse events were compared, and a cost‐effectiveness analysis was performed.Results: The study included 34 patients treated with pulsed Act‐D and 26 patients treated with 5‐day Act‐D. Overall complete remission was observed in 21 (62%) patients in the pulsed Act‐D group and 19 (73%) patients in the 5‐day Act‐D group (P=0.355); the mean number of treatment courses were 5.1 and 5.3, respectively (P=0.686). When Act‐D failed, patients in each group required 4.9 and 4.6 courses, respectively, of a multi‐agent regimen (P=0.545). No major adverse events were observed but moderate adverse events were more frequent in the pulsed Act‐D group (P=0.011). The 5‐day Act‐D regimen was more expensive compared with pulsed Act‐D regimen (US$7504.33 vs $5541.79), with an incremental cost‐effectiveness ratio of $64 557.08 per avoidance of treatment failure.Conclusion: Pulsed Act‐D was more cost‐effective than 5‐day Act‐D and could be preferred when considering Act‐D as chemotherapy for low‐risk GTN.Keywords
Funding Information
- Science and Technology Department of Sichuan Province
- Health and Family Planning Commission of Sichuan Province
This publication has 18 references indexed in Scilit:
- Relationship between race and clinical characteristics, extent of disease, and response to chemotherapy in patients with low-risk gestational trophoblastic neoplasiaGynecologic Oncology, 2015
- Comparison of pulsed actinomycin D versus 5‐day methotrexate for the treatment of low‐risk gestational trophoblastic diseaseInternational Journal of Gynecology & Obstetrics, 2011
- Treatment of Low-Risk Gestational Trophoblastic NeoplasiaJournal of Clinical Oncology, 2011
- Gestational trophoblastic diseaseThe Lancet, 2010
- Phase II trial of pulse dactinomycin as salvage therapy for failed low‐risk gestational trophoblastic neoplasiaCancer, 2006
- What is the best protocol of single-agent methotrexate chemotherapy in nonmetastatic or low-risk metastatic gestational trophoblastic tumors? A review of the evidenceGynecologic Oncology, 2006
- Single-agent pulse dactinomycin has only modest activity for methotrexate-resistant gestational trophoblastic neoplasiaGynecologic Oncology, 2004
- Is Lack of Response to Single-Agent Chemotherapy in Gestational Trophoblastic Disease Associated with Dose Scheduling or Chemotherapy Resistance?Gynecologic Oncology, 2002
- Combination Chemotherapy with Methotrexate, Etoposide, and Actinomycin D for High-Risk Gestational Trophoblastic TumorsGynecologic Oncology, 2000
- Decision making for chemotherapy administration in patients with low risk gestational trophoblastic neoplasiaInternational Journal of Gynecological Cancer, 1996